We're excited to share the positive results from the Tigris TRIAL of PMX hemoadsorption therapy for endotoxic septic shock (ESS): Results exceed the primary endpoint of 95% posterior probability of benefit for PMX on 28-day mortality. Read more: buff.ly/wP0GQ2a $EDT.TO

Congrats Spectral Medical Inc.! This is huge for all of us in the field!🔥

From one company fighting the effects of septic shock to a couple others.....a major CONGRATS from SeaStarMedical to Vantive Health and Spectral Medical Inc. on these results of the #TigrisTrial! Way to go!!

Missed it live? Watch the replay of CEO Chris Seto & CMO Dr. John Kellum presenting the highly anticipated TIGRIS Trial topline results, followed by Q&A. buff.ly/SJ1NkyQ

Great to see #QUELIMMUNE getting a shout out in this month’s issue of American Society of Nephrology Kidney News magazine! #ICU kidneynews.org/downloadpdf/vi…

After months of hard work, our SCD-PED economic cost model manuscript is now officially published in Journal of Medical Economics. The burden of pediatric AKI is tremendous at nearly $400,000 per hospitalization. But our SCD-PED is estimated to save almost $70,000 per hospitalization.

✅Welcoming Children's Hospital to our #SAVE registry! clinicaltrials.gov/study/NCT06517…

With September being Sepsis Awareness Month, what better time to attend the Sepsis Alliance Unite for Sepsis Symposium and hear our CMO, Kevin K. Chung, MD and others speak about this important topic! sepsisalliance.regfox.com/unite-for-seps…

Surviving Sepsis Guidelines co-chair Dr. Laura Evans giving the plenary at the Unite for Sepsis Symposium. Sepsis Alliance

This weekend, SeaStarMedical will present 2 posters at the 5th International Symposium on AKI in Children, including early data from our #SAVERegistry and #QUELIMMUNE therapy. We hope to see you there! investors.seastarmedical.com/news/news-deta…

#CharlieMike

#AKICINCY is off to a great start!! Over 150 registrants from 13 countries! The first session all about the State of the Art today. Thanks to all the speakers.

Vedran Premuzic highlighting the benefits of #SCD in critically ill children. 🙏🏼 One #SAVE at a time.

Wonderful review of #SCD and Quelimmune at #AKICincy by Danielle Soranno

Big news over the weekend as we shared details on the first 21 patients treated with QUELIMMUNE at the 5th International #AKICincy meeting! No device-related adverse events and strong survival data extending to 90 days! investors.seastarmedical.com/news-releases/…

Awesome #AHHSA2025 inaugural meeting led by Dr. Kumar Sharma! Thank you for the invite! ⁦UT San Antonio⁩ ⁦UT Health San Antonio⁩

We're honored to be selected from over 100 applicants as a Top 10 finalist for the UCSF-Stanford Pediatric Device Consortium (PDC) and Midwest PDC Accelerator Pitch Competition on Nov. 3rd at UC San Francisco. If awarded, this grant will support expanding #QUELIMMUNE to pediatric

Our awesome nurse trainers, hard at work training new staff for the #NEUTRALIZE-AKI study! Pressing on with enrollments! #SCD #ICU